Hypothesis: Age-related accumulation of mitochondrial DNA (mtDNA) mutations in colonic epithelial stem cells triggers cytosolic release of mtDNA, activating the cGAS-STING pathway and downstream type I interferon signaling. This chronic innate immune activation induces transcriptional upregulation of DNMTs, promoting promoter hypermethylation of MMR genes (MGMT, PMS2, MSH2) and Wnt pathway inhibitors (SFRP2, DKK1, BMP3) in both mutant and adjacent wild-type crypts, creating a field of epigenetically synchronized cells with reduced DNA repair capacity and increased clonal fitness. The resulting MMR-deficient field enables hypermutation while simultaneously selects for stem cells with adaptive advantages, accelerating crypt fission and niche succession.

Mechanistic Reasoning: The research context establishes that inflammation accelerates MMR decline 1 and that field effects extend 10 cm from tumors 2, yet the upstream trigger linking aging to widespread epigenetic silencing remains unclear. Mitochondrial dysfunction represents this missing link. Colonic stem cells exhibit high metabolic demand and continuous exposure to luminal oxidants, rendering them particularly vulnerable to mtDNA accumulation. Unlike nuclear DNA, mtDNA lacks protective histones and efficient repair mechanisms, accumulating mutations at 10-100x the nuclear rate.

With age, mtDNA mutations impair the electron transport chain, increasing mitochondrial ROS production and membrane permeability. This leads to mtDNA release into the cytosol via BAX/BAK pores—a process documented in aging tissues and neurodegeneration but understudied in gastrointestinal epithelium. Cytosolic mtDNA activates cGAS, which produces the second messenger cGAMP, triggering STING-dependent TBK1-IRF3 signaling and type I interferon response. This chronic interferon signature upregulates DNMT1 and DNMT3B transcriptionally, establishing a methylation-prone state in both the mtDNA-mutant stem cell and neighboring cells through paracrine interferon signaling—explaining the field effect beyond local clonal expansion.

Simultaneously, interferon-induced ISG expression alters the stem cell niche, potentially favoring mutant clones with disrupted apoptotic signaling. This creates a feed-forward loop where MMR deficiency enables mutation accumulation in mtDNA repair genes, worsening oxidative stress, while the epigenetically primed field facilitates clonal sweeps via crypt fission 2. The model also accounts for young-onset CRC findings 3, since microbiome-derived genotoxins like colibactin cause mtDNA damage directly, potentially accelerating this pathway in younger populations.

Testable Predictions: Several predictions emerge from this model. First, human colonic epithelium from aged individuals (≥65 years) should show increased cytosolic mtDNA, cGAS activation, and STING phosphorylation compared to younger controls, correlating with MGMT promoter methylation in matched normal mucosa. Second, in vitro organoid models of colonic stem cells with induced mtDNA mutations will exhibit cGAS-STING activation, DNMT upregulation, and MMR gene promoter hypermethylation, reversible with cGAS or STING inhibitors. Third, mouse models with crypt-specific mtDNA depletion (TFAM knockout) will develop field-wide epigenetic alterations extending beyond individual crypts, with accelerated adenoma formation when combined with APC loss. Fourth, serum mtDNA copy number and cGAMP levels will correlate with methylation markers (MGMT, BMP3) in plasma from CRC screening cohorts, potentially enabling non-invasive field cancerization risk stratification.

This hypothesis is falsifiable: if cGAS-STING inhibition does not prevent MMR promoter methylation in aged colonic organoids, or if field effects occur independently of mitochondrial dysfunction, the model would be rejected.

References: The model synthesizes established links between age-related MMR deficiency 1, Wnt pathway silencing in field cancerization 2, and clonal expansion dynamics 2, while incorporating the emerging role of mtDNA-mediated inflammation in age-related disease—a mechanism that could unify sporadic CRC pathogenesis across age groups.